Search

Your search keyword '"Passeron, T."' showing total 1,037 results

Search Constraints

Start Over You searched for: Author "Passeron, T." Remove constraint Author: "Passeron, T."
1,037 results on '"Passeron, T."'

Search Results

4. AB1374 DEUCRAVACITINIB IN PLAQUE PSORIASIS: MAINTENANCE OF RESPONSE OVER 3 YEARS

5. Attitudes and behaviors regarding sun exposure in Japan compared to Europe and North America.

7. Thirty years of promoting sun safety in France: The messages are heard but not followed!

10. PCR256 Correlation of Patient-Reported Vitiligo Noticeability Scale With Physician-Assessed Facial Vitiligo Area Scoring Index Responses: Post Hoc Analyses From the True-V Trials of Ruxolitinib Cream in Vitiligo

11. EE577 Early Initiation of Guselkumab Increases Duration of Complete Remission (Psoriasis Area and Severity Index 100) in Patients With Moderate-to-Severe Psoriasis

13. Do regrets of parents about sun overexposure impact preventive measures applied on their children?

15. Le deucravacitinib dans le psoriasis en plaques : résultats de tolérance et d’efficacité à 4ans dans les essais de phase 3 POETYK PSO-1, PSO-2 et dans l’étude LTE

17. The impact of Methoxypropylamino Cyclohexenylidene Ethoxyethylcyanoacetate (MCE) UVA1 filter on pigmentary and ageing signs: An outdoors prospective 8‐week randomized, intra‐individual comparative study in two populations of different genetic background

18. Sun exposure behaviors as a compromise to paradoxical injunctions: Insight from a worldwide survey

19. Do regrets of parents about sun overexposure impact preventive measures applied on their children?

20. The impact of methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate (MCE) UVA1 filter on pigmentary and ageing signs: An outdoor prospective 8‐week randomized, intra‐individual comparative study in two populations of different genetic background

27. Impact on facial skin aging signs of a 1‐year standardized photoprotection over a classical skin care routine in skin phototypes II–VI individuals: A prospective randomized trial.

28. CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

34. Impact des antécédents de la maladie sur l’efficacité du ritlécitinib (PF-06651600) chez les patients atteints de pelade (alopecia areata) : analyse post hoc de l’étude de phase 2b/3 ALLEGRO

43. Effet d’un sérum dermo-cosmétique contenant de la viniférine dans la prise en charge de l’hyperpigmentation post-inflammatoire comparativement à un dépigmentant de référence

50. The use of lasers in vitiligo, an overview

Catalog

Books, media, physical & digital resources